Compare ADV & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADV | CLLS |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | France |
| Employees | 73000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.2M | 384.3M |
| IPO Year | N/A | 2014 |
| Metric | ADV | CLLS |
|---|---|---|
| Price | $39.26 | $3.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.83 | $8.33 |
| AVG Volume (30 Days) | ★ 68.0K | 25.8K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.63 | N/A |
| Revenue Next Year | $0.45 | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $1.33 |
| 52 Week High | $38.78 | $5.48 |
| Indicator | ADV | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 77.88 | 53.05 |
| Support Level | $1.00 | $3.93 |
| Resistance Level | N/A | $4.54 |
| Average True Range (ATR) | 3.07 | 0.15 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 100.00 | 33.33 |
Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.